menu
    • menu
    [{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Praxis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Connecta therapeutics","sponsor":"Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CTH120","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Connecta therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connecta therapeutics \/ Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain","highestDevelopmentStatusID":"6","companyTruncated":"Connecta therapeutics \/ Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Connecta therapeutics

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Connecta therapeutics

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTH120

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction

                            Details : CTH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fragile X Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 01, 2024

                            Lead Product(s) : CTH120

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Praxis Pharmaceutical

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Praxis Pharmaceutical

                            Spain arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relutrigine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE

                            Details : PRAX-562 is a first selective persistent sodium current blocker. Praxis plans to initiate a Phase 2 clinical trial in the first half of 2022 to explore the potential for PRAX-562 to treat a range of rare pediatric DEEs, including SCN2A-DEE and SCN8A-DEE.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 30, 2021

                            Lead Product(s) : Relutrigine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth